Biotech Values

[Doc328]

I saw that Revance just filed an sBLA for cervical dystonia. There was no firm PDUFA date in the PR. The median duration of the effect was 24 weeks at 125U and 20 weeks at 250U. This will get it in the neurology office. If competitively priced, insurers may also allow off label use for other indications such as upper limb spasticity (MS, stroke, CP) and maybe even migraine (botox patent still valid for this indication - also anti-CGRP's have cut into the chronic migraine niche)

https://investors.revance.com/news-releases/news-release-details/revance-submits-supplemental-biologics-license-application-sbla